Komori
Eisai (4523) · RiskFirst stated

Risks from Revisions to Pharmaceutical Laws and Regulations and Non-Compliance

First written in FY2017. . Latest entry: FY2017.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Regulatory and licensing continuity risk in the pharmaceutical and long-term care businessesA theme 25 companies write about · 25 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2021: 2 of 14 companies on the "Worse" side.

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 25 companies compared. The sentences above are computed from all 25.
Full recordFilings, disclosures and news, newest first
  1. FY2017First statedAnnual report

    「The pharmaceutical business is subject to various laws and regulations, including pharmaceutical regulations and product liability laws, and the enactment or revision of laws and regulations may have a material effect on business performance.」

    薬価改定とは別に、薬事規制・製造物責任等の法規制制定・改定や適合不能による回収・許認可取消し等をリスクとしている。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Eisai yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risks from Revisions to Pharmaceutical Laws and Regulations and Non-Compliance | Eisai Co.,Ltd. (4523) | Komori